Evotec Wins German Government Research Grant
News Nov 19, 2009
Evotec has announced that it has been granted up to €2.5 m in research funds from the BMBF, within the Neu2 consortium, to advance research and development activities on the target Serine Racemase for potential use in neuroprotection.
Evotec will use its drug discovery platform and expertise in progressing this program towards the clinic, particularly making use of its high quality compound library and proprietary fragment-based drug discovery platform.
The Neu2 consortium, including Evotec, MerckSerono, the European ScreeningPort GmbH, Bionamics GmbH, and the University Medical Center Hamburg-Eppendorf amongst others were successful against stiff competition in this nationwide competition. The goal of the competition is to strengthen the German pharmaceutical industry and to bring innovation to market. The winning consortium, within which Evotec plays an important role, focuses on developing therapeutics aimed at Multiple Sclerosis and other neurodegenerative diseases.
Dr Klaus Maleck, Chief Financial Officer of Evotec comments: “Evotec is pleased to work on identifying new drugs against neurodegenerative diseases within this consortium. At the same time, this grant represents a valuable alternative to financing our research without jeopardizing our patent position. The work has the potential to make major improvements to the quality of life of the patient and can have considerable, non-dilutive impact on our investment case.”
Compound as Effective as FDA-Approved Drugs Against Life-Threatening InfectionsNews
Purdue University researchers have identified a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the Food and Drug Administration to treat life-threatening infections while also appearing to be less susceptible to bacterial resistance.READ MORE
Chemists Design 'Mini-ecosystems' to Test Drug FunctionNews
Scripps Research scientists have solved a major problem in chemistry and drug development by using droplet-sized 'miniecosystems' to quickly see if a molecule can function as a potential therapeutic.READ MORE
Integrated Lead Discovery: An Evolving ToolboxNews
A new SLAS Discovery review article offers an informative guide to the established and emerging tools available for early drug discovery and screening, and provides illustrative scenarios demonstrating considerations that drive decisions on choice of lead discovery tactics.READ MORE